Smith+Nephew partners with HOPCo to provide AI-powered analytics and solutions to ASC customers
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) – the world’s largest, fully-integrated, musculoskeletal (MSK) value-based care and outcomes management company. This collaboration will focus on enhancing solutions for ASC customers, physicians, and their patients through HOPCo’s digital health and analytics platforms, myrecovery® and Vitals®
The partnership with HOPCo provides a comprehensive technology platform that encompasses all musculoskeletal procedures performed in the ASC segment. The AI-powered myrecovery platform enhances the clinical experience by utilizing patient engagement tools such as remote care management, real time communications, and remote therapeutic monitoring (RTM), while providing critical* quality outcome metrics through proprietary activity tracking technology, functional outcomes reporting, patient-reported outcomes (PROMs), and longitudinal data integration across a patient’s care journey. HOPCo’s Vitals platform provides tools, analytics, and dashboards to help Smith+Nephew customers deliver better, more efficient and coordinated care while also meeting value-based care requirements aiming to reduce cost.
"We are thrilled to partner with HOPCo and the ability to bring their innovative digital solutions to customers in the ASC across both our Orthopaedic and Sports Medicine businesses. The HOPCo solutions will allow our customers to unlock value in the ASC be it through the use of RTM, PROMs, or leveraging analytics to drive efficiencies. Their commitment to driving meaningful change in outcomes through data aligns perfectly with the strength and value of the CORI◊ Surgical System," said Craig Gaffin, President of Global Orthopaedics at Smith+Nephew. "This collaboration underscores our commitment to advancing orthopaedic surgery through innovative technology, improving patient outcomes, and transforming the future of healthcare."
Data from the CORI Surgical System’s ability to perform image-agnostic robotic-assisted knee surgeries will now be augmented with the powerful data-driven insights from HOPCo’s Vitals and AI-powered myrecovery digital solutions. The integrated digital platform will encompass some of the most advanced practice and health system analytics solutions available. Planned integration with Smith+Nephew’s intraoperative data from the CORI Surgical System through RI.INSIGHTS Data Visualization Platform will provide surgeons and healthcare providers with enhanced analytics to link personalized surgical planning, intra-operative decision-making, and PROMS tracking and optimization.
“Smith+Nephew is clearly committed to using outcomes data to enhance the value of its products and services,” said Dr. David Jacofsky, CEO and Chairman at HOPCo. “HOPCo’s myrecovery and Vitals platforms will allow Smith+Nephew to leverage unique longitudinal data to do just that, while simultaneously providing meaningful additional value to customers and improving patient outcomes.”
- ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
About HOPCo
Healthcare Outcomes Performance Company (HOPCo) is the global leader of integrated musculoskeletal value-based health outcomes management, digital analytics, practice management, and health system service line management. This includes comprehensive expertise across all MSK specialties, including orthopedics, spine, pain management, rehabilitation, neurosurgery, and neurology. HOPCo's integrated care, analytics, and facilities development platforms have proven to increase the quality of patient care while reliably reducing the total cost of MSK care across the care continuum for practices, health systems and payors alike. HOPCo's affiliated payors, practices and health systems successfully participate in highly efficient value-based contracting (bundled payments, population health programs, and other advanced risk-based arrangements) utilizing HOPCo's proprietary platforms, IT solutions, integrated analytics, advanced medical economics and standardized care pathways. Visit www.hopco.com to learn more.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
- 践行社会责任,助力乡村振兴 | 平安养老险广西分公司开展爱心捐赠公益慰问活动
- 炬芯科技的智能手表SoC采用了芯原的2.5D GPU IP
- 中信国际电讯CPC守正创新 AI创新方案喜迎两大奖
- 凌晨三点的直播间:致敬老一辈企业家创维商学院长黄宏生
- 世界经济论坛特别会议闭幕,全球领导人呼吁:探寻通往和平与繁荣的清晰、不可逆转路径应为全球首要任务
- 固原冷凉蔬菜发展新样本:树地标品牌标杆,谱区域经济新篇
- Io Therapeutics, Inc., presented data from studies of IRX4204
- 情系苏黔,绿色融合——丰尚成功举办绿色农牧与绿色能源苏黔两省产业对接交流会
- 年度“SaaS企业Top100”:联易融护航企业“出海路”
- 汇智聚力,共创未来--高斯宝电气全栈国产化AI算力生态交流会议圆满举办
- 2024柯尼卡美能达全国经销商大会汇“创想”之力,筑决胜之道
- 直击新声科技CMEF参展首日,20周年庆典启动仪式点燃新征程
- 跑得对 不白费:舒华I5智能跑步机 为家庭用户量身定制科学跑步方式
- 母婴童行业难现第二个“孩子王” 生而不同一路领先
- 共赴盛典,奢享荣光丨雅兰家纺2024秋冬新品品鉴暨招商大会隆重召开
- 选对赛道逆势翻盘,“健康”产业成普通人创业热门之选
- 共享档博新机遇-2024第二届智慧档案科技博览会
- 智能外呼系统:提升客户服务效率和满意度的利器
- 丽婴房2024秋冬订货会盛大启幕,秘境寻踪主题引领时尚新风潮
- 2024年度百强艺术家榜单——杜同建作品鉴赏
- 科勒公司携旗下五大品牌亮相第28届中国国际厨卫展 创想无界 缔造不凡
- Fortrea 推出改善临床研究中多样性和入选的综合解决方案
- 本田飞机公司达成250架HondaJet交付
- 《欧盟药理学杂志》调查显示瑞士SAIC认可度较高
- 林俊杰福州演唱会分享巡演主题初衷 赵露思、Cody Walker现身观众席
- 安徽养殖网:打造绿色养殖新篇章,引领行业创新发展
- 软文发布这样操作很简单
- Canva和MMA Global的最新调查发现,尽管存在投资缺口和人才库缩减问题,但高级营销人员仍将创意产出视为首要任务
- 中信银行“有温度”的金融服务让年味更浓
- 远光资金分析调控平台入选2024广东软件风云榜“优秀信息技术应用创新产品”
推荐
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯